Clinical trial

Treatment of Adiposity Related hypErTension (TARGET)

NCT01138423

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Aliskiren Normalized identity: aliskirenView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Moxonidine Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Hydrochlorothiazide Normalized identity: hydrochlorothiazideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (for aliskiren) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (for moxonidine and hydrochlorothiazide) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Treatment of Adiposity Related hypErTension (TARGET)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-08-01

PhasePHASE4

Conditions

Hypertensionunresolved

Abdominal Obesityunresolved

Metabolic Syndromeverified · MONDO: abdominal obesity-metabolic syndrome

Interventions

AliskirenDRUG · verified · RxNorm: aliskiren

MoxonidineDRUG

HydrochlorothiazideDRUG · verified · RxNorm: hydrochlorothiazide

Placebo (for aliskiren)DRUG

Placebo (for moxonidine and hydrochlorothiazide)DRUG

Sponsors & collaborators

UMC Utrechtlead sponsor

Novartis Pharmaceuticalscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01138423 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.